Skip to content
MarketScale
‹ Back to IndustriesSciences

Planting Crepe Myrtles: Avoiding Common Mistakes and Depth Issues

The video highlights common mistakes in planting crepe myrtles, focusing on improper soil placement which can suffocate roots. It emphasizes the importance of correct planting depth and maintaining a clear flare for the health of the tree. Wes Rivers provides expert insight into creating landscapes that facilitate tree growth and sustainability.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sunny Crutchfield · ArboristCrepe MyrtleDfw Tree Care ExpertsImproper Planting
Share
Planting Crepe Myrtles: Avoiding Common Mistakes and Depth Issues

Key takeaways

01

Improper soil placement around newly planted trees can hinder oxygen flow to the roots.

02

Maintaining a visible flare and proper planting depth is crucial for tree health.

03

Utilizing mulch instead of soil around the tree base ensures proper irrigation and root care.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Planting Crepe Myrtles: In this informative video, ISA Certified Arborist Wes Rivers delves into the common challenges faced by newly planted trees, particularly within new landscapes. The spotlight is on a crepe myrtle tree that has been incorrectly planted, shedding light on crucial mistakes to avoid. Upon its initial crepe myrtle planting, soil was piled around the base of the tree, inadvertently hindering oxygen flow to the root ball. Wes explains that while mulch is acceptable, covering the root ball with soil is ill-advised.

The video underscores the importance of a specialized ring around the tree’s base, designed to facilitate thorough irrigation. Utilizing mulch instead of soil prevents the encroachment of tree roots into the irrigation area. The video further highlights the absence of a visible flare on the multi-trunk crepe myrtle tree, suggesting a deep planting issue. This valuable insight emphasizes the significance of proper planting depth and the benefits of preserving the flare.

Discover more reasons why working with an arborist can safeguard the future of your trees!

Are you looking for a sustainable Dallas-Fort Worth tree care company that prioritizes the healthy landscapes?

Look no further than TreeNewal, your trusted partner in tree care.

Our team of ISA Certified Arborists is dedicated to providing comprehensive tree services that ensure the vitality of your trees. From maintaining and reviving newly planted and established trees to diagnosing and treating tree diseases, fungi, and pests, we have you covered.

We specialize in proper tree diagnosis and offer tailored maintenance and treatment plans to keep your trees thriving. Our experts apply top-quality fertilizer and soil conditioning products to enhance tree health from the roots up.

At TreeNewal, we understand that many trees suffer from improper planting practices. That’s why we offer specialized techniques such as air spading, root collar excavation, and vertical mulching to improve the longevity of your trees. Our goal is to create sustainable landscapes that stand the test of time.

We also provide tree surveys and mitigation services to assist homeowners, developers, and commercial clients in meeting local city tree preservation requirements. With our expertise, you can ensure compliance while preserving the natural beauty of your surroundings.

Call TreeNewal today to schedule a consultation with our knowledgeable team. Let us be your partners in preserving the beauty and longevity of your beloved trees.

Contact TreeNewal now and experience exceptional tree care services!

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Sunny Crutchfield
Sunny CrutchfieldDigital Media Strategist

Throughout her career, Sunny Crutchfield has honed her skills in crafting data-driven campaigns, maximizing social media presence, and optimizing online content for optimal engagement and conversions. Her deep understanding of various digital channels, including social media, search engine marketing, email marketing, and content marketing, allows her to develop comprehensive and integrated campaigns that deliver tangible results.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Samsung Biologics signs $262M manufacturing deal through 2033, pushing longer CDMO bookings

Samsung Biologics signs $262M manufacturing deal through 2033, pushing longer CDMO bookings

Samsung Biologics disclosed a $262 million biologics manufacturing contract running through 2033. The work will be produced at Songdo, South Korea. The deal lifts Samsung Biologics’ cumulative contract value above $21.9 billion, per BioPharm International.

  • 01Duration is the headline: Samsung Biologics’ new $262 million contract with an unnamed European pharma company runs through Dec. 31, 2033, a long-dated commitment for the Songdo site (per BioPharm International).
  • 02CDMO selection is drifting from “price per batch” to “operating model”: Samsung Biologics executives have framed CDMOs as extensions of sponsor operations, which raises expectations for transparency, change control, and schedule flexibility (per BioPharm International).

Sep 13, 2026

Robotic Systems Emerge for Cell and Gene Therapy Manufacturing

Robotic Systems Emerge for Cell and Gene Therapy Manufacturing

A September 2024 Cytotherapy paper describes a robotic cluster designed to automate manual steps in cell therapy manufacturing. Additional reviews published in 2019 and 2026, along with commentary from Genetic Engineering and Biotechnology News, discuss automation and AI as tools being explored for the cell and gene therapy manufacturing sector.

  • 01A robotic cluster combining a robotic arm with customized modules can handle standard cell therapy equipment (incubators, bioreactors, reagent bags) without requiring entirely new manufacturing platforms.
  • 02The system produced human CD8+ T cells with cell yields, viability and identity comparable to manual cultures while maintaining sterility, according to the Cytotherapy paper.
  • 03Manufacturing automation and AI are cited in industry analysis as potential solutions to skilled labor shortages and production scaling challenges, particularly for allogeneic therapies manufactured at larger scale.

Sep 13, 2026

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's 2024 report, covered by TechTarget in April 2024, estimated that a top-10 biopharma company could capture $5-7 billion in peak AI value over five years, with about 90% concentrated in R&D, manufacturing/supply chain, and commercial functions. McKinsey reported in November 2025 that despite rising AI investment, pharma companies have not yet seen shorter development timelines or better clinical success rates.

  • 01Deloitte estimates $5–7B peak AI value for top-10 biopharma firms over five years, with cost reductions appearing in 1–2 quarters and revenue gains taking 3–4 quarters.
  • 02McKinsey found pharma companies have not yet achieved shorter drug development timelines or improved preclinical and clinical success rates despite increased AI spending.
  • 03AI systems used in manufacturing, supply chain, and R&D functions may require validation under existing regulated systems frameworks like GAMP.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

Sunny Crutchfield
Sunny Crutchfield

Digital Media Strategist

Throughout her career, Sunny Crutchfield has honed her skills in crafting data-driven campaigns, maximizing social media presence, and optimizing online content for optimal engagement and conversions. Her deep understanding of various digital channels, including social media, search engine marketing, email marketing, and content marketing, allows her to develop comprehensive and integrated campaigns that deliver tangible results.

WR
Wes Rivers

ISA Certified Arborist

TreeNewal

Wes Rivers is an ISA Certified Arborist specializing in tree care and landscaping. With expertise in diagnosing and treating tree issues, he helps maintain healthy landscapes through proper planting and care techniques.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512